Ikena Oncology Current Ratio 2021-2025 | IMA
Ikena Oncology current ratio from 2021 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Ikena Oncology Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2025-03-31 |
$0.12B |
$0.01B |
13.31 |
| 2024-12-31 |
$0.13B |
$0.01B |
11.80 |
| 2024-09-30 |
$0.14B |
$0.01B |
15.32 |
| 2024-06-30 |
$0.15B |
$0.01B |
18.22 |
| 2024-03-31 |
$0.16B |
$0.01B |
15.85 |
| 2023-12-31 |
$0.18B |
$0.01B |
12.58 |
| 2023-09-30 |
$0.20B |
$0.02B |
10.41 |
| 2023-06-30 |
$0.16B |
$0.01B |
13.38 |
| 2023-03-31 |
$0.14B |
$0.01B |
10.12 |
| 2022-12-31 |
$0.16B |
$0.02B |
7.44 |
| 2022-09-30 |
$0.18B |
$0.03B |
7.11 |
| 2022-06-30 |
$0.20B |
$0.03B |
6.98 |
| 2022-03-31 |
$0.22B |
$0.03B |
8.53 |
| 2021-12-31 |
$0.24B |
$0.03B |
8.70 |
| 2021-09-30 |
$0.25B |
$0.03B |
8.24 |
| 2021-06-30 |
$0.27B |
$0.03B |
8.80 |
| 2021-03-31 |
$0.28B |
$0.03B |
9.44 |
| 2020-12-31 |
$0.17B |
$0.03B |
5.86 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.061B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
